# Satoshi Morita

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/satoshi-morita/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,011 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 85 |
| i10-index | 523 |
| Last Known Institution | Kyoto University |
| OpenAlex ID | https://openalex.org/A5101885138 |
| ORCID iD | https://orcid.org/0000-0002-4344-3317 |
| Works | 1,267 |

## Researcher papers

- [Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma](https://scholariq.org/papers/midterm-outcomes-in-patients-with-intermediate-sized-hepatocellular-carcinoma/)
- [Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial](https://scholariq.org/papers/discontinuation-of-dasatinib-in-patients-with-chronic-myeloid-leukaemia-who-have/)
- [2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease](https://scholariq.org/papers/2015-japanese-society-for-dialysis-therapy-guidelines-for-renal-anemia-in/)
- [Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme](https://scholariq.org/papers/phase-ii-clinical-trial-of-wilms-tumor-1-peptide-vaccination-for-patients-with/)
- [Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor](https://scholariq.org/papers/efficacy-of-osimertinib-plus-bevacizumab-vs-osimertinib-in-patients-with-i-egfr/)
- [Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial](https://scholariq.org/papers/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)
- [The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV](https://scholariq.org/papers/the-japanese-lung-cancer-society-guideline-for-non-small-cell-lung-cancer-stage/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Kyoto University](https://scholariq.org/institutions/kyoto-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.